Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.45 |
| ▸ | BRD2 | P25440 | 5/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927971 | 0.84 | BRD4 (0.64) | BRD4CREBBPMAPK14 | |
| SCHEMBL18538408 | 0.81 | BRD4 (0.36) | BRD4CREBBP | |
| SCHEMBL18164465 | 0.75 | BRD4 (0.62) | BRD4CREBBPMAPK14 | |
| SCHEMBL18164470 | 0.74 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL20160233 | 0.70 | BRD4 (0.55) | BRD4BRD2BRD3 | |
| SCHEMBL16651455 | 0.67 | BRD4 (0.73) | BRD4CREBBP | |
| SCHEMBL16650976 | 0.67 | BRD4 (0.51) | BRD4CREBBP | |
| SCHEMBL21994212 | 0.67 | BRD4 (0.41) | BRD4CREBBPPTGS2MAPK14 | |
| SCHEMBL16651076 | 0.66 | BRD4 (0.72) | BRD4CREBBPMAPK14 | |
| SCHEMBL16651476 | 0.65 | CREBBP (0.48) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | BRD4 5/4885BRD2 8/4885BRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.